We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Aspirin for People in Their 40s Could Reduce Cancer Risk

By LabMedica International staff writers
Posted on 21 May 2009
Individuals in their 40s could cut their risk of cancer developing later in life by taking aspirin, according to research. More...


In a study examining all current evidence, the investigators published their findings in the journal Lancet Oncology on April 29, 2009. Cancer Research UK (London) scientists suggest that taking aspirin at an age before cancer begins to develop--and for at least 10 years--would maximize the compound's potential to prevent cancer.

Previous research suggests that people who take aspirin are less likely to develop colon cancer, breast cancer, and possibly some other types of cancer. Aspirin blocks the effects of the cyclooxygenase (COX) enzymes, proteins involved in inflammation and found at unusually high levels in several types of cancer. But regular use of the anti-inflammatory drug specifically for cancer prevention is not currently recommended as it has been linked to a number of side effects including, gastrointestinal bleeding, and stomach ulcers.

Common cancers, such as prostate, breast, lung and bowel, tend to develop after the age of 60. Moreover, the chances of aspirin causing bleeding in the abdomen are much higher in people over 60.

Study author, Prof. Jack Cuzick, from the Cancer Research UK Center for Epidemiology at Queen Mary, University of London, said, "Taking aspirin regularly in your mid-40s could maximize the effect this drug has on preventing cancer. Taking aspirin at this age, which is about the time precancerous lesions usually begin to develop, may be the best time to stop the disease from progressing to actual cancer. And, as the risk of serious side effects of aspirin greatly increase after 60 years old, taking long-term treatment before this age will help to minimize these side effects.”

However, according to Prof. Cuzick, many questions need to be answered before physicians could advise routine use of aspirin for cancer prevention. More studies and clinical trials are needed to better identify those people who are at high risk of developing cancers and at low risk of side effects, who will benefit most from aspirin treatment. He reported that some studies did not show a preventative effect, but the follow-up was less than 10 years, so it may have been too early to see the effect.

"For older patients--who are already taking aspirin for cardiovascular disease--the drug may also provide additional protection against some cancers, but it is not yet known whether a ‘baby aspirin' can achieve this, or if the full standard dose of 300 mg/day will be needed,” Prof. Cuzick stated.

The researchers also found that taking aspirin in combination with other drugs known as proton pump inhibitors could help to lower the risk of stomach bleeding. The AspECT trial, funded by Cancer Research UK, is investigating the use of proton pump inhibitors and aspirin in patients with Barrett's esophagus--a precancerous condition that can develop into gullet cancer.

Dr. Lesley Walker, Cancer Research UK's director of cancer information, said, "We need scientists to focus their efforts on how to reduce the side effects of taking aspirin so that very soon it may be possible to use the drug as a way of preventing cancer. It's too soon to recommend that people take aspirin to try and stop cancer developing because of the side effects. But, survival is low for cancers like gullet cancer so understanding how to prevent the disease is crucial. It's important that any decision to take aspirin regularly is only made in consultation with a GP [general practitioner].”

Related Links:
Cancer Research UK


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.